<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱

INNO 406 - Bafetinib

產(chǎn)品貨號

Axon 2121 CAS [859212-16-1] MF C30H31F3N8OMW 576.62 Purity: 99% Optical purity: Optically pure Soluble in 0.1N HCl(aq) and DMSO Description Orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy; orally bioavailable; more potent (>10 times) than Imatinib; highly recommended Abl inhibitor in treating chronic myeloid leukaemia (CML) References Certificates Categories Extra info A Yokota et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109(1), 306-314. ? H Kantarjian et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116(11), 2665-72.? ? JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.? Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology BCR-ABL Lyn Oncogene Fusion Proteins EC 2.7.10.1 Dual Bcr-Abl and Lyn kinase inhibitor Chemical name (S)-N-(3-(4,5'-bipyrimidin-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide Parent CAS No. [859212-16-1] Order Size Unit Price Stock 2 mg €85.00 In Stock

產(chǎn)品價格

現(xiàn)貨詢價，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

INNO 406 - Bafetinib

Based on 16 reference(s) in Google Scholar 9 10 16

Axon 2121

CAS [859212-16-1]

MF C30H31F3N8O
MW 576.62

Purity: 99%
Optical purity: Optically pure
Soluble in 0.1N HCl(aq) and DMSO

INNO 406

Description

Orally bioavailable dual Bcr-Abl and Lyn kinase inhibitor with anti-CML efficacy; orally bioavailable; more potent (>10 times) than Imatinib; highly recommended Abl inhibitor in treating chronic myeloid leukaemia (CML)

A Yokota et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood, 2007, 109(1), 306-314.

H Kantarjian et al. Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance. Cancer, 2010, 116(11), 2665-72.?

JC Uitdehaag et al. A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets. Br. J. Pharmacol. 2012, 166, 858–876.?

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & Oncology BCR-ABL Lyn Oncogene Fusion Proteins EC 2.7.10.1

Dual Bcr-Abl and Lyn kinase inhibitor

Chemical name

(S)-N-(3-(4,5'-bipyrimidin-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide

Parent CAS No.

[859212-16-1]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>